Bioventus initiated with an Outperform at Barrington

Barrington initiated coverage of Bioventus (BVS) with an Outperform rating and $13 price target The firm sees the company posting mid-to-high single-digit sales growth over the next several years. Bioventus is an “under-the-radar” medical technology idea, the analyst tells investors in a research note.